Novel Antifungal Drug Discovery Based on Targeting Pathways Regulating the Fungus-Conserved Upc2 Transcription Factor
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Infections by Candida albicans and related fungal pathogens pose a serious health problem for immunocompromised patients. Azole drugs, the most common agents used to combat infections, target the sterol biosynthetic pathway. Adaptation to azole therapy develops as drug-stressed cells compensate by upregulating several genes in the pathway, a process mediated in part by the Upc2 transcription factor. We have implemented a cell-based high-throughput screen to identify small-molecule inhibitors of Upc2-dependent induction of sterol gene expression in response to azole drug treatment. The assay is designed to identify not only Upc2 DNA binding inhibitors but also compounds impeding the activation of gene expression by Upc2. An AlphaScreen assay was developed to determine whether the compounds identified interact directly with Upc2 and inhibit DNA binding. Three compounds identified by the cell-based assay inhibited Upc2 protein level and UPC2-LacZ gene expression in response to a block in sterol biosynthesis. The compounds were growth inhibitory and attenuated antifungal-induced sterol gene expression in vivo . They did so by reducing the level of Upc2 protein and Upc2 DNA binding in the presence of drug. The mechanism by which the compounds restrict Upc2 DNA binding is not through a direct interaction, as demonstrated by a lack of DNA binding inhibitory activity using the AlphaScreen assay. Rather, they likely inhibit a novel pathway activating Upc2 in response to a block in sterol biosynthesis. We suggest that the compounds identified represent potential precursors for the synthesis of novel antifungal drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Gallo-Ebert et al. found that 3 inhibitors (VB00075177, VB00075853, and VB00074845) reduced the expression of both mRNA and protein levels of UPC2 and demonstrated that these compounds ' inhibiting effect of DNA-binding is irrelevant to the direct interaction with Upc2p.”
From The synthesis, regulation, and functions of sterols in Candida albicans: Well-known but still lots to learn (2016) · cites this paper as [58]
Citations
Cites
Transformation of intact yeast cells treated with alkali cations
Ito, H., Fukuda, Y., Murata, K., & Kimura, A. (1983) · Journal of Bacteriology · doi:10.1128/jb.153.1.163-168.1983 · Cited by 7,518
Genomic Expression Programs in the Response of Yeast Cells to Environmental Changes
Gasch, A. P., Spellman, P. T., Kao, C. M., Carmel-Harel, O., Eisen, M. B., Storz, G., Botstein, D., & Brown, P. O. (2000) · Molecular Biology of the Cell · doi:10.1091/mbc.11.12.4241 · Cited by 4,815
[10] Yeast promoters and lacZ fusions designed to study expression of cloned genes in yeast
Guarente, L. (1983) · Methods in Enzymology · doi:10.1016/0076-6879(83)01013-7 · Cited by 1,071
Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment
Pfaller, M. A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.11.001 · Cited by 903 · cited 1×
“glabrata are on the rise, due to acquisition of azole drug resistance (61, 62).”
BackgroundNon-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance
Krcmery, V., & Barnes, A. J. (2002) · Journal of Hospital Infection · doi:10.1053/jhin.2001.1151 · Cited by 733
A Fungal Family of Transcriptional Regulators: the Zinc Cluster Proteins
MacPherson, S., Larochelle, M., & Turcotte, B. (2006) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00015-06 · Cited by 612 · cited 3×
“Upc2 is a member of the fungus-conserved Zn2-Cys6 binuclear cluster TFs (25).”
BackgroundInfluentialYeast: An Experimental Organism for 21st Century Biology
Botstein, D., & Fink, G. R. (2011) · Genetics · doi:10.1534/genetics.111.130765 · Cited by 604
Importance of Candida Species Other than C. albicans as Pathogens in Oncology Patients
Wingard, J. R. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.1.115 · Cited by 542
An insight into the antifungal pipeline: selected new molecules and beyond
Ostrosky-Zeichner, L., Casadevall, A., Galgiani, J. N., Odds, F. C., & Rex, J. H. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3074 · Cited by 432 · cited 1×
“There are several classes of sterol pathway targeting drugs, the most common being the azoles, which includes the N-substituted imidazoles fluconazole and miconazole and the new triazole derivatives itraconazole and posaconazole (12).”
BackgroundCoste, A. T., Karababa, M., Ischer, F., Bille, J., & Sanglard, D. (2004) · Eukaryotic Cell · doi:10.1128/ec.3.6.1639-1652.2004 · Cited by 407
Cited by
The antifungal pipeline: a reality check
Perfect, J. R. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.46 · Cited by 866
Kumari, A., & Singh, R. K. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103578 · Cited by 244
Structural mechanism of ergosterol regulation by fungal sterol transcription factor Upc2
Yang, H., Tong, J., Lee, C. W., Ha, S., Eom, S. H., & Im, Y. J. (2015) · Nature Communications · doi:10.1038/ncomms7129 · Cited by 223
Antifungals: Mechanism of Action and Drug Resistance
Prasad, R., Shah, A. H., & Rawal, M. K. (2016) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-25304-6_14 · Cited by 183
Antifungal drugs: New insights in research & development
Nicola, A. M., Albuquerque, P., Paes, H. C., Fernandes, L., Costa, F. F., Kioshima, E. S., Abadio, A. K. R., Bocca, A. L., & Felipe, M. S. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.10.008 · Cited by 139
Novel Agents and Drug Targets to Meet the Challenges of Resistant Fungi
McCarthy, M. W., Kontoyiannis, D. P., Cornely, O. A., Perfect, J. R., & Walsh, T. J. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix130 · Cited by 169
Gsaller, F., Hortschansky, P., Furukawa, T., Carr, P. D., Rash, B., Capilla, J., Müller, C., Bracher, F., Bowyer, P., Haas, H., et al. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005775 · Cited by 133
Emerging New Targets for the Treatment of Resistant Fungal Infections
Liu, N., Tu, J., Dong, G., Wang, Y., & Sheng, C. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01413 · Cited by 139
Lv, Q.-Z., Yan, L., & Jiang, Y.-Y. (2016) · Virulence · doi:10.1080/21505594.2016.1188236 · Cited by 133
Elucidating Drug Resistance in Human Fungal Pathogens
Xie, J. L., Polvi, E. J., Shekhar-Guturja, T., & Cowen, L. E. (2014) · Future Microbiology · doi:10.2217/fmb.14.18 · Cited by 100
Transcriptional control of hyphal morphogenesis in Candida albicans
Villa, S., Hamideh, M., Weinstock, A., Qasim, M. N., Hazbun, T. R., Sellam, A., Hernday, A. D., & Thangamani, S. (2020) · FEMS Yeast Research · doi:10.1093/femsyr/foaa005 · Cited by 116
A complex game of hide and seek: the search for new antifungals
Ngo, H., Garneau‐Tsodikova, S., & Green, K. D. (2016) · MedChemComm · doi:10.1039/c6md00222f · Cited by 81
Liu, J., Yuan, Y., Wu, Z. Q., Li, N., Chen, Y., Qin, T., Geng, H., Li, X., & Liu, D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117115 · Cited by 42
Joshua, I., & Höfken, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040772 · Cited by 40
“The absence of UPC2 orthologs in humans, the role of Upc2 in azole resistance and potentially other important roles in Candida pathogenesis make Upc2 an interesting target for novel antifungal drugs [93].”
BackgroundVu, B. G., Stamnes, M. A., Li, Y., Rogers, P. D., & Moye-Rowley, W. S. (2021) · PLOS Genetics · doi:10.1371/journal.pgen.1009582 · Cited by 39
Gsaller, F., Hortschansky, P., Furukawa, T., Carr, P. D., Rash, B. M., Capilla, J., Müller, C., Bracher, F., Bowyer, P., Haas, H., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1006106 · Cited by 35
Rational Discovery of (+) (S) Abscisic Acid as a Potential Antifungal Agent: a Repurposing Approach
Khedr, M. A., Massarotti, A., & Mohamed, M. E. (2018) · Scientific Reports · doi:10.1038/s41598-018-26998-x · Cited by 28
Woods, K., & Höfken, T. (2016) · Molecular Microbiology · doi:10.1111/mmi.13244 · Cited by 23
“Upc2 therefore represents a potential new target for antifungal drugs (Gallo-Ebert et al., 2014).”
BackgroundAntifungal drug screening: thinking outside the box to identify novel antifungal scaffolds
Beattie, S. R., & Krysan, D. J. (2020) · Current Opinion in Microbiology · doi:10.1016/j.mib.2020.03.005 · Cited by 21
“The use of other reporter strains has been applied to identify molecules that interfere with critical pathways such as zinc and iron homeostasis [24,25] and the sterol regulatory transcription factor Upc2 [26].”
BackgroundHe, F., Zhang, X., Mafurah, J. J., Zhang, M., Qian, G., Wang, R., Safdar, A., Yang, X., Liu, F., & Dou, D. (2016) · Microbial Pathogenesis · doi:10.1016/j.micpath.2016.02.018 · Cited by 20
Yang, S., Chen, Y., Yuan, Z., Bu, F., Jiang, C., & Ding, Z. (2020) · Organic & Biomolecular Chemistry · doi:10.1039/d0ob01987a · Cited by 10
Kumar, S., Bishnoi, P., Chauhan, N., Kumar, P., & Aggarwal, R. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2515812 · Cited by 7
Carbonic anhydrases from pathogens
Bonardi, A., Gratteri, P., & Nocentini, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816476-1.00019-8 · Cited by 6
Integrated Analysis Identifies Interaction Patterns between Small Molecules and Pathways
Li, Y., Li, W., Chen, X., Jiang, H., Sun, J., Chen, H., & Lv, S. (2014) · BioMed Research International · doi:10.1155/2014/931825 · Cited by 5
“Azole drugs, which are commonly used in infection treatment, play a part in azole therapy by targeting the sterol biosynthetic pathway [11].”
Editorial: Lipids in host microbe interaction
Porter, E. M., Sáiz, J., & Nickels, J. T. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.1002856 · Cited by 3
“On the other hand, lipids play also important roles in microbial physiology and a better understanding of their regulation and function in microbes can open distinct approaches to novel antimicrobial drug design (Gallo-Ebert et al., 2014).”
BackgroundSelf-citationHirai, K., Inukai, T., & Nakayama, H. (2016) · Medical Mycology Journal · doi:10.3314/mmj.16.007 · Cited by 2
(2014) · Egyptian Journal of Botany · doi:10.21608/ejbo.2014.490 · Cited by 2
Bahn, Y., Lee, S., Sun, S., Jang, Y.-B., Yu, S.-R., Choi, J.-T., Choi, Y., Kim, E.-S., Lee, J.-S., Heitman, J., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9581746/v1 · Cited by 1
“In C. albicans , for example, the TF Upc2, which regulates sterol synthesis and is responsive to azole treatment, has been exploited to screen for small molecules that inhibit its expression or DNA binding 92 .”
Hirai, K., Inukai, T., & Nakayama, H. (2017) · Medical Mycology Journal · doi:10.3314/mmj.17.007
Shekhar‐Guturja, T. (2016) · TSpace (University of Toronto)
The pseudosymmetric crystal structure of 2-(2-naphthalenyl)-3-nitro-2H-1-benzopyran, C38H26N2O6
Hong, Z., Zhan, Y.-L., Yu, D.-R., Li, Y., Yuan, W.-J., & Zhang, H. (2017) · Zeitschrift für Kristallographie - New Crystal Structures · doi:10.1515/ncrs-2017-0047
“[5], antifungal activity [6], flavodoxin inhibitors against”
Combinatorial approach to combat drug resistance in human pathogenic fungi
Mir, M. A., Qadri, H., Aisha, S., & Shah, A. H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-96127-1.00011-5
Lee, S., Sun, S., Jang, Y.-B., Yu, S.-R., Choi, Y., Choi, Y., Kim, E.-S., Lee, J.-S., Cowen, L. E., Heitman, J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.30.722081
BindingDB Entry 50002345: Emerging New Targets for the Treatment of Resistant Fungal Infections.
BindingDB (2020) · UC San Diego · doi:10.7270/q26112x4
Vu, B. G., Stamnes, M. A., Li, Y., Rogers, P. D., & Moye-Rowley, W. S. (2021) · doi:10.1371/journal.pgen.1009582.r002
Metadata
- Authors
- Gallo-Ebert, C., Donigan, M., Stroke, I. L., Swanson, R. N., Manners, M. T., Francisco, J., Toner, G., Gallagher, D., Huang, C.-Y., Gygax, S. E., Webb, M., & Nickels, J. T.
- Affiliations
- The Institute of Metabolic Disorders, Genesis Biotechnology Group, Hamilton, New Jersey, USA
- Venenum Biodesign, Genesis Biotechnology Group, Hamilton, New Jersey, USA
- Femeris, Women's Health Research Center, Medical Diagnostic Laboratories, Genesis Biotechnology Group, Hamilton, New Jersey, USA
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2014-01
- Volume
- 58
- Issue
- 1
- Pages
- 258-266
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3910738
- OpenAlex
- W2099462216
- Cited by
- 32
- References
- 69
- Citations by year
- 2026: 2 · 2025: 1 · 2022: 2 · 2021: 2 · 2020: 4 · 2019: 1 · 2018: 3 · 2017: 5 · 2016: 6 · 2015: 4 · 2014: 2
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- antifungal drug discovery, Candida albicans, azole resistance, sterol biosynthesis, small molecule inhibitors, AlphaScreen, high-throughput screening, fungal pathogens
- MeSH terms
- Antifungal Agents, Candida albicans, Fungal Proteins, Transcription Factors, Signal Transduction, Gene Expression Regulation, Fungal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.